Costello J F, Futscher B W, Kroes R A, Pieper R O
Neuroscience Program, Loyola University Chicago, Maywood, Illinois 60153.
Mol Cell Biol. 1994 Oct;14(10):6515-21. doi: 10.1128/mcb.14.10.6515-6521.1994.
There is considerable interest in identifying factors responsible for expression of the O-6-methylguanine DNA methyltransferase (MGMT) gene, as MGMT is a major determinant in the response of glioma cells to the chemotherapeutic agent 1,3 bis(2-chloroethyl)-1-nitrosourea. Recently we have shown that MGMT expression is correlated in a direct, graded fashion with methylation in the body of the MGMT gene and in an inverse, graded fashion with promoter methylation in human glioma cell lines. To determine if promoter methylation is an important component of MGMT expression, this study addressed the complex interactions between methylation, chromatin structure, and in vivo transcription factor occupancy in the MGMT promoter of glioma cell lines with different levels of MGMT expression. Our results show that the basal promoter in MGMT-expressing glioma cell lines, which is 100% unmethylated, was very accessible to restriction enzymes at all sites tested, suggesting that this region may be nucleosome free. The basal promoter in glioma cells with minimal MGMT expression, however, which is 75% unmethylated, was much less accessible, and the basal promoter in nonexpressing cells, which is 50% unmethylated, was entirely inaccessible to restriction enzymes. Despite the presence of the relevant transcription factors in all cell lines examined, in vivo footprinting showed DNA-protein interactions at six Sp1 binding sites and one novel binding site in MGMT-expressing cell lines but no such interactions in nonexpressors. We conclude that in contrast to findings of previous in vitro studies, Sp1 is an important component of MGMT transcription. These correlations also strongly suggest that methylation and chromatin structure, by determining whether Sp1 and other transcription factors can access the MGMT promoter, set the transcriptional state of the MGMT gene.
人们对确定负责O-6-甲基鸟嘌呤DNA甲基转移酶(MGMT)基因表达的因素有着浓厚兴趣,因为MGMT是胶质瘤细胞对化疗药物1,3-双(2-氯乙基)-1-亚硝基脲反应的主要决定因素。最近我们发现,在人类胶质瘤细胞系中,MGMT表达与MGMT基因主体的甲基化呈直接的梯度相关,与启动子甲基化呈相反的梯度相关。为了确定启动子甲基化是否是MGMT表达的重要组成部分,本研究探讨了不同MGMT表达水平的胶质瘤细胞系中甲基化、染色质结构和体内转录因子占据情况之间的复杂相互作用。我们的结果表明,表达MGMT的胶质瘤细胞系中的基础启动子,其甲基化程度为100%未甲基化,在所有测试位点对限制酶都非常易接近,这表明该区域可能无核小体。然而,MGMT表达极低的胶质瘤细胞中的基础启动子,其甲基化程度为75%未甲基化,易接近性要低得多,而不表达MGMT的细胞中的基础启动子,其甲基化程度为50%未甲基化,对限制酶完全不可接近。尽管在所检测的所有细胞系中都存在相关转录因子,但体内足迹分析显示,在表达MGMT的细胞系中,DNA与蛋白质在六个Sp1结合位点和一个新的结合位点发生相互作用,而在不表达MGMT的细胞中则没有这种相互作用。我们得出结论,与之前体外研究的结果相反,Sp1是MGMT转录的重要组成部分。这些相关性还强烈表明,甲基化和染色质结构通过决定Sp1和其他转录因子能否接近MGMT启动子,设定了MGMT基因的转录状态。